ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE:IMUC) today announced that Andrew Gengos, Chief Executive Officer, will present a corporate overview and business update at the 17th Annual BIO CEO & Investor Conference at 2:00 pm ET on Monday, February 9, 2015, at the Waldorf Astoria Hotel in New York City… Read more »
Shares of ImmunoCellular Therapeutics closed yesterday at $0.7 . IMUC has a 1-year high of $1.52 and a 1-year low of $0.53. The stock’s 50-day moving average is $0.73 and it’s 200-day moving average is $0.81.
On the ratings front, ImmunoCellular Therapeutics (NYSE:IMUC) has been the subject of a number of recent research reports. In a report issued on December 1, Maxim Group analyst Jason Kolbert maintained a Buy rating on IMUC, with a price target of $4, which represents a potential upside of 471.4% from where the stock is currently trading. Separately, on November 17, Roth Capital`s Joseph Pantginis reiterated a Buy rating on the stock and has a price target of $3.
ImmunoCellular Therapeutics Ltdis a clinical-stage biotechnology company that develops immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors.